High-dose FOLFIRI, surgery, and radiofrequency ablation for patients with unresectable liver metastases from colorectal cancer

To evaluate a strategy combining high-dose 5FU-irinotecan-leucovorin (HD-FOLFIRI) chemotherapy, radiofrequency ablation and surgery in patients with unresectable liver metastases from colorectal cancer. Patients, all presenting UDP glucuronosyl transferase-1A1 (UGT1A1) 6/6 or 6/7 genotype, received...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2013-04, Vol.33 (4), p.1603-1607
Main Authors: Hebbar, Mohamed, Truant, Stéphanie, Desauw, Christophe, Sergent-Baudson, Geraldine, Cattan, Stephane, Piessen, Guillaume, Pruvot, François-Rene
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Camptothecin - administration & dosage
Camptothecin - analogs & derivatives
Catheter Ablation
Colorectal Neoplasms - mortality
Colorectal Neoplasms - pathology
Colorectal Neoplasms - therapy
Combined Modality Therapy
Dose-Response Relationship, Drug
Feasibility Studies
Female
Fluorouracil - administration & dosage
Genotype
Glucuronosyltransferase - genetics
Humans
Leucovorin - administration & dosage
Liver Neoplasms - mortality
Liver Neoplasms - secondary
Liver Neoplasms - therapy
Male
Middle Aged
Neoplasm Staging
Polymerase Chain Reaction
Survival Rate
Treatment Outcome
Young Adult
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate a strategy combining high-dose 5FU-irinotecan-leucovorin (HD-FOLFIRI) chemotherapy, radiofrequency ablation and surgery in patients with unresectable liver metastases from colorectal cancer. Patients, all presenting UDP glucuronosyl transferase-1A1 (UGT1A1) 6/6 or 6/7 genotype, received HD-FOLFIRI (with high-dose irinotecan: 260 mg/m(2)), one cycle every two weeks. The feasibility of local therapy (surgery and/or radiofrequency) was assessed every four cycles. The objective of therapy was the complete clearance rate of metastases. The trial was terminated after inclusion of 18 out of the 40 planned patients due to insufficient recruitment. The median number of metastases was seven (range=2-30). On intention-to-treat analysis, six patients (33.3%) received local treatment of metastases with complete clearance of metastases in each case. Median progression-free and overall survivals were 15.3 months and 33.7 months, respectively. The assessed strategy is feasible and allows for a complete clearance of metastases in one third of patients, with prolonged survival.
ISSN:1791-7530